Skip to main content

Peptide vaccine

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

  • RegistryNCT05950139
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionNSCLC Stage IV
  • SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
How ARCHER worksNCT059501391 min

What the film says

Read the transcript

For lung cancer driven by an ALK gene fusion, targeted pills work well, sometimes for years. Then resistance arrives; it almost always does.

The idea: vaccinate while the drug is still working, so the immune system learns the tumor before it changes.

The ALK fusion protein exists only in cancer cells, which makes it a clean target. At Johns Hopkins, patients whose disease is stable on an ALK inhibitor receive a peptide vaccine, fragments of the ALK protein with an immune adjuvant, to raise T cells against any cell carrying it. So when drug-resistant cells emerge, the immune system is already watching.

ARCHER is a small early safety study; the drug continues throughout. Vincent Lam leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05950139

    ALK inhibitors effective; acquired resistance near-universal; Vaccinate during stable disease on crizotinib/ceritinib/alectinib/brigatinib/lorlatinib; Peptide vaccine + adjuvant; Vincent Lam; Johns Hopkins; enrollment 12

The drug

What is being tested.

The study drug is a prophylactic cancer peptide vaccine for advanced ALK-positive non-small cell lung cancer.

The study

How the trial runs.

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)
  • Documented ALK rearrangement as detected by: (1) fluorescence in situ hybridization (FISH), (2) immuno-histochemistry (IHC), (3) tissue next-generation sequencing (NGS), or (4) circulating tumor DNA (ctDNA) NGS
  • Ongoing treatment with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with at least stable disease ≥ 4 months
  • No known presence of the specific ALK acquired resistance alterations targeted by the study vaccine
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Males or females at least 18 years old

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.